ClinicalTrials.gg
Not yet recruitingNCT07620366Updated Oct 22, 2026

To Evaluate the Efficacy and Safety of QL2401 in Patients With Metabolic Dysfunction-associated Steatohepatitis and Liver Fibrosis

A Phase 2 interventional study of QL2401 25 mg and QL2401 50 mg in Metabolic Dysfunction-associated Steatohepatitis (MASH), sponsored by Qilu Pharmaceutical Co., Ltd.. Not yet recruiting. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-10-22.

Sponsored by Qilu Pharmaceutical Co., Ltd. · Phase 2, Interventional, and Treatment

Updated Oct 22, 2026Start date movedEligibility revised+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
132
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Study summary

This is a Phase II, multicenter, randomized, double-blind, placebo-controlled, parallel-design clinical trial to evaluate efficacy and safety of QL2401 in patients with metabolic dysfunction-associated steatohepatitis and liver fibrosis (F2-F3).

02

Conditions studied

  • Metabolic Dysfunction-associated Steatohepatitis (MASH)

Browse trials for

03

In context

Fatty Liver

664 studies on the registry are indexed under Fatty Liver; 186 are open to participants now.

This study's planned enrollment of 132 is above the median of 60 across 433 interventional studies indexed under Fatty Liver.

Browse Fatty Liver studies →

Lead sponsor

Qilu Pharmaceutical Co., Ltd. is the lead sponsor of 200 studies on the registry; 122 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

The criteria were revised on the registry on Oct 22, 2026. See what changed

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Males and females between 18 - 80 years of age inclusive, based on the date of signation of ICF.
  2. Presence of type 2 diabetes, or diagnosed at least 1 diseases of obesity, dyslipidemia, hypertension, elevated fasting glucose.
  3. Any one criterion as follow:

    • Liver proved MASH (NAS ≥ 4 with steatosis, ballooning degeneration and lobular inflammation ≥ 1) with fibrosis stage 2 to 3 at screening or within 6 months; or
    • VCTE measured liver stiffness 8.0 kPa ≤ LSM \< 20.0 kPa, CAP>302 dB/m.
  4. Hepatic fat fraction > 10% measured by MRI-PDFF at screening.
  5. Participants using weight loss, blood sugar-lowering, or lipid-regulating medications must maintain a stable dose for ≥3 months before randomization.
  6. Participants maintain a stable body weight (±5%) within 2 months prior screening.

Exclusion criteria

Exclusion Criteria:

  1. Currently or prior history of hepatocellular carcinoma.
  2. Previous or planned liver transplant.
  3. History or evidence of any acute or chronic liver disease other than MASH.
  4. Cirrhosis with histological records available during screening or prior (stage 4 fibrosis).

Other inclusion and exclusion criteria may apply.

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
132 participants (estimated)

Study arms

  • Experimental
    QL2401 25 mg

    Drug: QL2401 25 mg

  • Experimental
    QL2401 50 mg

    Drug: QL2401 50 mg

  • Experimental
    QL2401 100 mg

    Drug: QL2401 100 mg

  • Placebo comparator
    QL2401 placebo 25 mg

    Drug: QL2401 placebo 25 mg

  • Placebo comparator
    QL2401 placebo 50 mg

    Drug: QL2401 placebo 50 mg

  • Placebo comparator
    QL2401 placebo 100 mg

    Drug: QL2401 placebo 100 mg

Interventions

  • DrugQL2401 25 mg

    QL2401 is a recombinant fusion protein administered via subcutaneous injection. Participants will receive QL2401 25 mg, once-weekly for 48 weeks.

  • DrugQL2401 50 mg

    QL2401 is a recombinant fusion protein administered via subcutaneous injection. Participants will receive QL2401 50 mg, once-weekly for 48 weeks.

  • DrugQL2401 100 mg

    QL2401 is a recombinant fusion protein administered via subcutaneous injection. Participants will receive QL2401 100 mg, once-weekly for 48 weeks.

  • DrugQL2401 placebo 25 mg

    Matching placebo administered via subcutaneous injection, once-weekly for 48 weeks.

  • DrugQL2401 placebo 50 mg

    Matching placebo administered via subcutaneous injection, once-weekly for 48 weeks.

  • DrugQL2401 placebo 100 mg

    Matching placebo administered via subcutaneous injection, once-weekly for 48 weeks.

06

What researchers measure

Primary outcomes

  1. Changes in liver fat content (%) measured by magnetic resonance imaging-proton density fat fraction (MRI-PDFF) at week 12 relative to baseline

    Change from baseline in hepatic fat fraction, measured by MRI-PDFF

    Time frame: Baseline to Week 12

07

Study locations

No study locations are listed for this record.

08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2026; primary completion for Jun 2027, 6 months later.

Of 41 phase 2 interventional studies under Fatty Liver, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 36. This study's planned 6 months is below that.

Start moved once since we started tracking on Sep 25, 2026: Jun 2026 → Dec 2026, on Oct 22, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
May 27, 2026
First posted
Jun 2, 2026
StartEst.
Dec 2026was Jun 2026
Primary completionEst.
Jun 2027
CompletionEst.
Mar 2028
Last update
Oct 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Jun 2026→Dec 2026
Oct 22, 2026
Eligibility
2 inclusion criteria edited
What changed in the criteria
Inclusion criteria
  • EditedMales and females between 18 - 7580 years of age inclusive, based on the date of signation of ICF.
  • EditedHepatic fat fraction > 10% measured by MRI-PDFF at screening or within 3 months.
Oct 22, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • EditedChanges in liver fat content (%) measured by magnetic resonance imaging-proton density fat fraction (MRI-PDFF) at week 2412 relative to baselineTime frame: Baseline to Week 24 → Baseline to Week 12
Oct 22, 2026
Title
To Evaluate the Efficacy and Safety of QL2401 in Patients With Metabolic Dysfunction-associated Steatohepatitis and Liver Fibrosis (F2-F3)
Oct 22, 2026
Show all 1 update
  1. Oct 22, 2026
    Start date Jun 2026→Dec 2026
    Eligibility 2 inclusion criteria edited
    What changed in the criteria
    Inclusion criteria
    • EditedMales and females between 18 - 7580 years of age inclusive, based on the date of signation of ICF.
    • EditedHepatic fat fraction > 10% measured by MRI-PDFF at screening or within 3 months.
    Primary outcomes 1 edited
    What changed in the outcomes
    • EditedChanges in liver fat content (%) measured by magnetic resonance imaging-proton density fat fraction (MRI-PDFF) at week 2412 relative to baselineTime frame: Baseline to Week 24 → Baseline to Week 12
    Title To Evaluate the Efficacy and Safety of QL2401 in Patients With Metabolic Dysfunction-associated Steatohepatitis and Liver Fibrosis (F2-F3)

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07620366
Responsible party
Sponsor
First posted
Jun 2, 2026
Start date
Dec 2026 (estimated)
Primary completion
Jun 2027 (estimated)
Completion
Mar 2028 (estimated)
Last update
Oct 22, 2026

Study contacts

Dandan Guo, Master
Contact
dandan1.guo@qilu-pharma.com
+86-0531-55821372

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion